Biotechnology · Healthcare
CEO, Board Member
2026-03-16–present
Board Member
Hepion Pharmaceuticals, Inc. (HEPA)Equibles does not estimate personal net worth.
Get an email with a short summary when Hepion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get HEPA alertsSireesh Appajosyula is recorded as CEO at Hepion Pharmaceuticals, Inc. (HEPA) since October 9, 2026 and Board Member at Hepion Pharmaceuticals, Inc. (HEPA) since March 16, 2026. Hepion Pharmaceuticals, Inc. reported in an 8-K filed October 9, 2026 that Sireesh Appajosyula was appointed Chief Executive Officer, effective October 9, 2026. Hepion Pharmaceuticals, Inc. reported in an 8-K filed March 18, 2026 that Sireesh Appajosyula was appointed director, effective March 16, 2026. Hepion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Hepion Pharmaceuticals, Inc. includes Dr. Kaouthar Lbiati (CEO), Gary Stetz (CEO, CFO and Board Member), John Cavan (CEO and CFO) and 7 others.
“On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.”
“On March 16, 2026, the Board approved the appointment of Gary Stetz as interim Chief Executive Officer of the Company and director and appointed Vincent LoPriore as Executive Chairman, Sireesh Appajosyula as director and Chase LoPriore as director.”
2026-10-09–present
2026-03-16–present
Biotechnology · Healthcare
CEO, Board Member
2026-03-16–present